In this phase 2 trial, patients with acute CHF, HTN (SBP >125) and mild-to-moderate renal insufficiency (GFR 30-75) were randomized to placebo or several doses of relaxin (human peptide that increases vasodilation and renal function). The relaxin group had improved dyspnea scores, shorter length of stay, and reduced CV death/CHF readmissions. Serious adverse events were similar between the groups. If confirmed in phase 3 studies, this will likely be a valuable addition to inpatient management of acute CHF (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]